Aim: To test the hypothesis that different magnitude of resistance of denervated skeletal muscle to nondepolarizing muscle relaxants (NDMRs) is related to their varying potencies at ε-AChR and γ-AChR. Methods: Both innervated and denervated mouse muscle cells, and human embryonic kidney 293 (HEK293) cells expressing ε-AChR or γ-AChR were used. The effects of NDMRs on nAChR were explored using whole-cell patch clamp technique. Results: NDMRs vecuronium (VEC), atracurium (ATR) and rocuronium (ROC) produced reversible, dose-dependent inhibition on the currents induced by 30 μmol/L acetylcholine both in innervated and denervated skeletal muscle cells. Compared to those obtained in innervated skeletal muscle cells, denervation shifted the concentration-response curves rightward and significantly increased the 50% inhibitory concentration (IC 50 ) values (VEC: from 11.2 to 39
Introduction
Thermal injury and other forms of critical illness can cause denervation of skeletal muscle [1] . Denervation in turn causes pharmacological changes in skeletal muscle, with the main changes leading to potentially lethal hyperkalemia in response to the depolarizing muscle relaxant succinylcholine and resistance to nondepolarizing muscle relaxants (NDMRs), typified by d-tubocurarine (dTC) [2, 3] . Up-regulation (increase) of nicotinic acetylcholine receptors (nAChR) explains some of these pharmacological responses [4, 5] . nAChRs include two subtypes: the adult form (ε-AChR) composed of α 2 βδε subunits and the fetal form (γ-AChR) containing α 2 βδγ subunits [6, 7] . γ-AChR is initially expressed in fetal muscle, and then replaced by ε-AChR when muscles are innervated. However, after denervation of adult muscles, γ-AChR is expressed de novo throughout the muscle membrane [8] . Clinically-used NDMRs competitively occupy the α δ and α ε (or α γ ) sites of the nAChR to achieve muscle relaxation during surgery and artificial ventilation. Denervation causes up-regulation of nAChRs and AChRγ mRNA [5, 9] to increase the doses of NDMRs needed to competitively bind to nAChR. Also, expression of γ-AChR after denervation has clinical significance, because the two subtypes have different electrophysiological and drug-binding properties [10] . Previous data have confirmed that denervated skeletal muscle displays resistance to NDMRs [5, 11] and that potencies of different NDMRs are different at ε-AChR and γ-AChR [12] [13] [14] . Interestingly, Narimatsu et al [15] observed that the magnitude of sepsis-induced attenuation of potencies of NDMRs depends on the kind of neuromuscular blocker.
The hypothesis of this study was that denervation would cause different magnitudes of resistance to different NDMRs due to their varying potencies at nAChR subtypes. The aim of this study was to test differences in the magnitude of resistance to vecuronium, atracurium, and rocuronium, which are commonly used NDMRs, in denervated skeletal muscle. 
Isolation of muscle fibres
Single skeletal muscle cells from the flexor digitorum brevis (FDB) muscle were obtained from the hindfeet of each mouse. The muscles were incubated for 3 h with Dulbecco's modified Eagle's medium (DMEM) (Invitrogen TM , Grand Island, NY, USA) containing 10% fetal calf serum (Invitrogen TM , Grand Island, NY, USA), 100 µg/mL penicillin-streptomycin, and 0.2% collagenase 1A (Sigma Chemical Co, Saint Louis, USA) in a shaking bath at 37 °C. After 3 h of enzymatic treatment, the muscles were dissociated into single muscle cells using Pasteur pipettes with different tip sizes. Fibre length and width were measured using an ocular micrometer with 100 µm divisions. The fibres were viewed with a 40× objective, producing an optical resolution of 2.5 µm between the divisions. Half the distance between the divisions was easily resolved, giving a measurement error of ±1.25 µm.
Expression of nAChR in HEK293 cells
Expression plasmids Psp65α, Psp65β, Psp65δ, Psp64γ, and Pbssk(+)ε, encoding complementary DNA coding sequences for the mouse muscle nAChR subunits α, β, δ, γ, and ε, respectively, were provided by the Salk Institute in America. These plasmids were subcloned in pcDNA3.1 + (Invitrogen TM Life Technologies, Carlsbad, CA, USA). HEK293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% calf serum, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37 °C in a 5% CO 2 /95% O 2 incubator. The HEK293 cells were transfected stably with Lipofectamine 
Electrophysiology
A conventional patch clamp technique with a whole cell configuration was used [16] . All experiments were performed at room temperature (20-24 °C). Patch pipettes were pulled from borosilicate glass using a Flaming Brown micropipette puller (P97; Sutter Instrument Co, Novato, CA, USA), ranging from 1 to 2 MΩ. The pipette electrode was filled with the following solution (mmol/L): 140 KCl, 10 HEPES, 10 EGTA, 1 CaCl 2 , and 1 MgCl 2 , and the pH was adjusted to 7.2 with KOH. The external solution contained (mmol/L): 5 KCl, 140 NaCl, 1 CaCl 2 , 1.25 MgCl 2 , 10 HEPES, and 10 glucose, with 0.5 µmol/L atropine sulfate, and pH was adjusted to 7.4 with NaOH. The cells were voltage-clamped at -80 mV in a whole-cell configuration after obtaining GΩ seals. 60%-80% of the series resistance was compensated for. Currents were recorded with an EPC10 amplifier (HEKA Elektronik, Germany) and PatchMaster software (HEKA Elektronik, Germany), sampled at 10 kHz or 20 kHz, and stored on a computer.
Acetylcholine (ACh) and atropine sulfate were purchased from Sigma (Saint Louis, USA). Muscle relaxants were obtained in preparations for clinical use: rocuronium, vecuronium (NV Organon, Netherlands), and atracurium (Jiangsu Hengrui Medicine Co, China). All drugs were dissolved in the external solution and applied by a gravity-driven perfusion system. Solutions and their dilutions to the experimental concentrations were prepared immediately before the experiments.
An agonist concentration of 30 µmol/L ACh was used for all experiments. Test solution containing either ACh 30 µmol/L alone or in combination with various concentrations of antagonist (NDMRs) were applied for 10 s to muscle cells and 5 s to HEK293 cells, and the peak current was determined. To determine the effect of the antagonist on the 30 µmol/L ACh-elicited current, the antagonist-containing solutions perfused the cells for 3 min prior to application of the solution of ACh 30 µmol/L plus the antagonist. The washout time between each drug application was at least 60 s in order to minimize the amount of desensitization throughout the course of an experiment. Currents were acquired from five muscle cells taken from five different mice or five HEK293 cells. The control current to ACh 30 µmol/L alone was repeated after washout of the antagonist. We took the mean value of these two ACh applications as the average control current, and calculated the antagonist response (percentage inhibition of average control current) using the equation:
Statistical Analysis
Data analysis was performed off-line using Origin 8 (OriginLab, Northampton, MA, USA) and GraphPad Prism 4 (Graphpad software, Inc, San Diego, CA, USA). Concentrationresponse curves were fitted to the four-parameter logistic equation by nonlinear regression analysis, and the inhibition concentrations for the half-maximal responses (IC 50 ) were determined. Results were represented as mean±SD. Statistical significance was assessed using one-way analysis of variance followed by Tukey's test and unpaired or paired two-tailed Student's t-tests. P<0.05 was considered significant. ACh at different concentrations (1-500 µmol/L) was applied for 10 s to innervated mouse skeletal muscle cells. ACh elicited concentration-dependent inward currents. The data were fitted to a logistic equation. The ACh concentrations producing 50% of the maximal response (EC 50 ) were 27.1 µmol/L for the nAChR in the innervated skeletal muscle (data not shown). In all following experiments, a concentration of 30 µmol/L was used to activate nAChR because this concentration was close to the EC 50 concentration and smaller than the estimated transient peak concentrations within the neuromuscular junction [17] , but it elicited sufficient current responses without significant desensitization after repetitive application.
Next, we examined the effects of denervation on potency of the three clinically-used NDMRs by applying ACh to innervate or denervate skeletal muscle. We found that they reversibly inhibited ACh-elicited inward currents in a concentrationdependent manner (Figures 1 and 2) . The rank order of potency using the IC 50 concentrations for innervated skeletal muscle was vecuronium>atracurium>rocuronium and for denervated skeletal muscle was vecuronium>rocuroniumã tracurium. Compared with innervated skeletal muscle, in denervated skeletal muscle the IC 50 values of vecuronium, atracurium, and rocuronium increased 3.7-, 5.5-, and 2.8-fold, respectively. Therefore, the rank order of the magnitude of resistance to the three NDMRs in denervated skeletal muscle, assessed by looking at the incremental fold in the IC 50 values, was atracurium>vecuronium~rocuronium (Table 1) .
Potency of muscle relaxants on nAChR subtypes
To further determine potency of the three NDMRs on nAChR We observed that all NDMRs reversibly inhibited the ACh-elicited currents in a concentration-dependent way (Figures 3 and 4) .
In a comparison of IC 50 values, rocuronium was more potent at γ-AChR, but atracurium was more potent at ε-AChR; no significant difference was found for vecuronium. The rank order of potencies according to the estimated IC 50 values for (Table 2) . Together, these results suggest that differences of resistance to the NDMRs caused by denervation may be related to their potencies on nAChR subtypes.
Discussion
In this study, we used a whole-cell patch clamp technique on acutely dissociated skeletal muscle cells and a HEK293 cell expression system to investigate the effect of denervation on the potency of vecuronium, atracurium, rocuronium, and the possible mechanisms. We used a holding voltage of -80 mV because the antagonistic effects of NDMRs are independent of holding voltages ranging from -100 to -40 mV [12, 13] . We established our denervation model in mice [18, 19] . We obtained innervated and denervated skeletal muscle cells 7 d after denervation. Compared with the values obtained from innervated skeletal muscle cells, the IC 50 values of vecuronium, atracurium, and rocuronium in the denervated skeletal muscle cells were significantly larger. This indicates that denervation leads to resistance to NDMRs in skeletal muscle, a finding that has been reported by others [5, 11] . A possible mechanism for this resistance to NDMRs is that skeletal muscle denervation causes up-regulation of mature and immature nAChRs on the muscle membrane [9, 20] , which would increase the amount of NDMR required to competitively block ACh [10] . Ibebunjo and Martyn [2, 5] reported that total (mature and immature) AChR protein on the tibialis muscle increased 5.4-fold (P<0.05) compared to the contralateral control tibialis on d 7 after a burn. In this study, the IC 50 values of vecuronium, rocuronium, and atracurium in denervated muscle cells increased 3.7-, 2.8-, and 5.5-fold, respectively, compared with innervated muscle cells.
We also observed that IC 50 ratios in innervation and denervation were different among the tested NDMRs, thus indicating that denervation caused different magnitudes in potency of the tested NDMRs. Comparing IC 50 ratios, we found that post-denervation resistance to NDMRs was greater to atracurium than to vecuronium or rocuronium. We presumed that this different magnitude of resistance to NDMRs is associated with the presence of γ-AChR because there are different potencies of NDMRs on γ-AChR and ε-AChR [12] [13] [14] . So, we studied the action of the tested NDMRs at γ-and ε-AChR expressed in HEK293 cells and observed that rocuronium had greater potency at γ-AChR than at ε-AChR; vecuronium had equipotent effects at both receptor subtypes; and atracurium was less potent at γ-AChR than at ε-AChR. Thus, we deemed that after denervation, resistance to atracurium was greater, which is consistent with the known lesser potency of atracurium at γ-AChR compared with the potency at ε-AChR, and resistance to rocuronium was less, which again is consistent with a greater potency at γ-AChR than at ε-AChR.
Knowing the different magnitudes of resistance to NDMRs in denervated skeletal muscle is important for clinicians. Denervation causes a larger dose requirement to muscle relaxants to achieve desired clinical effect, but this requirement to different muscle relaxants is variable; therefore, monitoring of neuromuscular function is clinically essential to specifically determine the dose requirement of muscle relaxants and help reduce potential adverse events.
In summary, this study demonstrates that denervation leads to different magnitudes of resistance to NDMRs in mouse skeletal muscle. We observe different potencies of vecuronium, atracurium, and rocuronium at ε-AChR and γ-AChR expressed in HEK293 cells. Our findings suggest that the phenomenon of different magnitudes of resistance to NDMRs in denervated mouse skeletal muscle is due to the different potencies of individual NDMRs at nAChR subunits. 
